You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and its global biologics research and development arm, MedImmune, has announced the results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, in severe, uncontrolled asthma. In STRATOS 2, tralokinumab did not achieAlready a subscriber Login You have read all your…
Norway's BerGenBio has finished up a $15 million round to push its lead Axl kinase inhibitor into new Phase I and Phase II studies for acute myeloid leukemia. BerGenBio is in the early stages of developing a pipeline of epithelial-mesenchymal transition (EMT) inhibitors, with three antibodies andAlready a subscriber Login…
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in previously treated patients with advanced adenocarcinomAlready a subscriber Login You have read all your free articles, to continue…
Bioarctic Neuroscience has announced that the first patients in Sweden have been treated with BAN2401 in a clinical study for patients with an early type of Alzheimer's disease. BAN2401 is a monoclonal antibody that has been developed in the laboratory of Professor Lars Lannfeldt at Uppsala UniveAlready a subscriber Login…
